These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 27960557)

  • 41. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
    Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
    Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vedolizumab for the treatment of ulcerative colitis.
    Shahidi N; Bressler B; Panaccione R
    Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology.
    Bonovas S; Pansieri C; Piovani D; Macaluso FS; Orlando A; Festa S; Papi C; Pugliese D; Armuzzi A
    Dig Liver Dis; 2022 Apr; 54(4):428-439. PubMed ID: 35183439
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

  • 45. Vedolizumab for the treatment of moderately to severely active ulcerative colitis.
    Dulai PS; Mosli M; Khanna R; Levesque BG; Sandborn WJ; Feagan BG
    Pharmacotherapy; 2015 Apr; 35(4):412-23. PubMed ID: 25884529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Up-to-date surgery for ulcerative colitis in the era of biologics.
    Yamamoto T; Carvello M; Lightner AL; Spinelli A; Kotze PG
    Expert Opin Biol Ther; 2020 Apr; 20(4):391-398. PubMed ID: 31948294
    [No Abstract]   [Full Text] [Related]  

  • 48. Biosimilars in paediatric inflammatory bowel disease.
    Sieczkowska-Golub J; Jarzebicka D; Oracz G; Kierkus J
    World J Gastroenterol; 2018 Sep; 24(35):4021-4027. PubMed ID: 30254406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis.
    Trigo-Vicente C; Gimeno-Ballester V; García-López S; López-Del Val A
    Int J Clin Pharm; 2018 Dec; 40(6):1411-1419. PubMed ID: 30478492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The safety of biological pharmacotherapy for the treatment of ulcerative colitis.
    Fiorino G; Bonovas S; Cicerone C; Allocca M; Furfaro F; Correale C; Danese S
    Expert Opin Drug Saf; 2017 Apr; 16(4):437-443. PubMed ID: 28279079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Biosimilar monoclonal antibodies: the scientific basis for extrapolation.
    Schellekens H; Lietzan E; Faccin F; Venema J
    Expert Opin Biol Ther; 2015; 15(11):1633-46. PubMed ID: 26365396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Positioning Therapy for Ulcerative Colitis.
    Grinspan A; Kornbluth A
    Curr Gastroenterol Rep; 2015 Aug; 17(8):29. PubMed ID: 26143627
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New molecules in the treatment of inflammatory bowel disease].
    Chaparro M; Gisbert JP
    Gastroenterol Hepatol; 2016; 39(6):411-23. PubMed ID: 26631943
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis.
    Veny M; Garrido-Trigo A; Corraliza AM; Masamunt MC; Bassolas-Molina H; Esteller M; Arroyes M; Tristán E; Fernández-Clotet A; Ordás I; Ricart E; Esteve M; Panés J; Salas A
    J Crohns Colitis; 2021 Mar; 15(3):441-452. PubMed ID: 32926095
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis.
    Kurnool S; Nguyen NH; Proudfoot J; Dulai PS; Boland BS; Vande Casteele N; Evans E; Grunvald EL; Zarrinpar A; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2018 Jun; 47(11):1472-1479. PubMed ID: 29665045
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
    Renna S; Mocciaro F; Ventimiglia M; Orlando R; Macaluso FS; Cappello M; Fries W; Mendolaro M; Privitera AC; Ferracane C; Pisana V; Magnano A; Pluchino D; Inserra G; Scarpulla G; Garufi S; Carroccio A; Siringo S; Di Mitri R; Cottone M; Orlando A
    Dig Liver Dis; 2018 Dec; 50(12):1292-1298. PubMed ID: 30007516
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of biological therapy in pediatric patients with Crohn's disease.
    Tarnok A; Kiss Z; Kadenczki O; Veres G
    Expert Opin Biol Ther; 2019 Mar; 19(3):181-196. PubMed ID: 30601083
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biological therapy for ulcerative colitis: an update.
    Seo GS; Chae SC
    World J Gastroenterol; 2014 Oct; 20(37):13234-8. PubMed ID: 25309060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.